Generation Bio Co. (GBIO)
After hours:
| Previous Close | 1.1300 |
| Open | 1.1300 |
| Bid | 1.3700 x 1000 |
| Ask | 1.4700 x 1100 |
| Day's Range | 1.1300 - 1.5600 |
| 52 Week Range | 0.8600 - 7.3500 |
| Volume | |
| Avg. Volume | 642,876 |
| Market Cap | 91.848M |
| Beta (5Y Monthly) | 2.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9700 |
| Earnings Date | Feb 21, 2024 - Feb 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
GlobeNewswireGeneration Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue Strategic reorganization will result in a 40% reduction of workforce Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating ge
- GlobeNewswire
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291.0 million expected to fund operations into 2026 CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE N
GlobeNewswireGeneration Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
Figure 1 mRNA expression with T cell ctLNP in humanized mouse model Figure 2 Dose response with T cell ctLNP in humanized mouse model Figure 3a Half-life of stealth LNP in NHPs and mice Figure 3b Biodistribution of stealth LNP in NHPs 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolon
